No orange book, no problem: Due diligence for biologics and biosimilars

Journal of Bioanalysis & Biomedicine

ISSN: 1948-593X

Open Access

No orange book, no problem: Due diligence for biologics and biosimilars

2nd International Conference and Exhibition on Biowaivers & Biosimilars

September 23-25, 2013 Hilton Raleigh-Durham Airport at RTP, NC, USA

Sanya Sukduang

Accepted Abstracts: J Bioanal Biomed

Abstract :

Over the past twenty-eight years, branded and generic pharmaceutical companies have come to rely on the FDA?s Orange Book to identify the relevant patents covering pharmaceuticals. The regulations set forth in the Biologics Price, Competition, and Innovation Act (?BPCIA?), which govern the FDA approval process for biologics and biosimilars, however, do not require companies to publicly list patents covering branded biological products. As such, companies are forced to conduct their own due diligence to identify relevant patents. This session will address the patent disclosure requirements in the BPCIA and discuss due diligence tips and tactics for both branded and biosimilar companies seeking to identify relevant patents protecting FDA approved biologics.

Google Scholar citation report
Citations: 3099

Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report

Journal of Bioanalysis & Biomedicine peer review process verified at publons

Indexed In

arrow_upward arrow_upward